Valuation: Celldex Therapeutics, Inc.

Market Cap 2.63B 2.31B 2.17B 1.98B 3.71B 252B 3.74B 26.08B 10.11B 129B 9.88B 9.67B 417B P/E 2026 *
-7.99x
P/E 2027 * -7.85x
Enterprise Value 1.97B 1.73B 1.62B 1.49B 2.78B 189B 2.8B 19.51B 7.57B 96.17B 7.39B 7.23B 312B EV / Sales 2026 *
1,064x
EV / Sales 2027 * 201x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celldex Therapeutics, Inc.

1 day-6.86%
1 week-19.50%
Current month-21.37%
1 month-23.19%
3 months-5.52%
6 months-2.01%
Current year+14.73%
1 week 30.39
Extreme 30.39
41.62
1 month 30.39
Extreme 30.39
42.12
Current year 22.33
Extreme 22.33
45.14
1 year 22.1
Extreme 22.1
45.14
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
57.2
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 2014-07-29
Chief Executive Officer 64 2008-08-31
Director of Finance/CFO 55 2009-03-31
Director TitleAgeSince
Director/Board Member 64 2008-11-30
Chairman 80 2025-06-04
Director/Board Member 93 2008-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/25/26 Free

Executive/Senior Manager

20,000 0.0255%
6/25/26 Free

Director

26,000 0.0331%
6/25/26 Free

Chief Technology Officer

57,000 0.0726%
Change 5-day change 1-year change 3-year change Capi.($)
-6.73%-19.50%+28.60%+20.59% 2.63B
-0.18%+4.35%+4.23%+30.02% 47.86B
-0.29%-0.16%+43.95%+32.61% 44.46B
-1.43%+4.26%+10.28%+90.62% 41.85B
-1.21%-2.42%+332.46%+548.03% 41.34B
-0.62%-0.06%+10.15%+46.02% 30.04B
-1.58%+0.42%+24.76%+152.96% 17.59B
-6.16%-9.74% - - 15.6B
-3.55%+1.95%+21.97%+39.13% 15.69B
-1.11%+9.12%-9.25% - 13.93B
Average -2.35%+1.09%+51.91%+120.00% 27.1B
Weighted average by Cap. -1.39%+1.73%+67.98%+141.12%

Financials

2026 *2027 *
Net sales 1.85M 1.62M 1.53M 1.4M 2.61M 177M 2.63M 18.33M 7.11M 90.35M 6.95M 6.79M 293M 9.95M 8.74M 8.21M 7.51M 14.03M 954M 14.14M 98.65M 38.24M 486M 37.38M 36.56M 1.58B
Net income -319M -280M -263M -241M -450M -30.57B -453M -3.16B -1.23B -15.59B -1.2B -1.17B -50.54B -361M -317M -298M -272M -509M -34.58B -513M -3.58B -1.39B -17.63B -1.36B -1.33B -57.15B
Net Debt -662M -581M -546M -500M -934M -63.44B -940M -6.56B -2.54B -32.35B -2.49B -2.43B -105B -633M -556M -523M -478M -893M -60.68B -900M -6.28B -2.43B -30.94B -2.38B -2.33B -100B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
26-09-23 $31.01 -7.48% 2,724,493
26-09-22 $33.51 -11.56% 12,888,897
26-09-21 $37.89 -0.92% 549,512
26-09-18 $38.24 -1.90% 2,081,882
26-09-17 $38.98 +0.70% 1,278,921
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
33.51USD
Average target price
62.50USD
Spread / Average Target
+86.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLDX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!